

# Alfamino®

WIC, Medicaid and SNAP eligible\*\*

Aim *higher* with more MCTs for GI Intolerances

Alfamino® hypoallergenic amino acid-based formulas are made with the highest % MCTs among amino acid-based formulas for infants and children with multiple food allergies and malabsorptive conditions.



Alfamino® formulas were associated with 70% fewer healthcare visits and 86% reduction in total associated costs after switching from Elecare®#



	Alfamino®	Elecare®	<p>Alfamino® formulas were associated with</p> <p><b>58%</b></p> <p>less reports of GI intolerance<sup>^</sup> symptoms after switching from Elecare® formulas<sup>^^</sup></p>
Made with Free amino acids, the building blocks of protein	✓	✓	
Has MCTs to facilitate fat absorption	✓	✓	
Infant * ( < 1 year)	<b>43%</b>	<b>33%</b>	
Junior * (1-13 years)	<b>65%</b>	<b>33%</b>	

\*Percentage of overall fat content as MCT

WHERE TO BUY

NestleNutritionStore.com  
DMEs, Pharmacies

amazon

H-E-B

<sup>^</sup> GI intolerance symptoms included abdominal distension, constipation, diarrhea, flatulence and nausea & vomiting

<sup>^^</sup> 148 patients pre-switch vs. 61 patients at 1 month post-switch

<sup>#</sup> A mean of 76 visits pre-switch vs. a mean of 23 visits at 1 month post-switch ; \$679,401 vs. \$92,922 at 1 month post-switch

<sup>\*\*</sup> WIC is a registered service mark of the US Department of Agriculture for USDA's Special Supplemental Nutrition Program for Women, Infants and Children.

Check with your State WIC Agency for local policies regarding coverage. No endorsement of any brand or product by the USDA is implied or intended.

Requires state medical documentation form. State approval is subject to change. MEDICAID is a property of the U.S. Department of Health and Human Services and the Centers for Medicare & Medicaid Services. No endorsement of any brand or product by the DHHS and/or CMS is implied or intended.

The SNAP logo is a service mark of the U. S. Department of Agriculture. USDA does not endorse any goods, services, or enterprises.

Elecare is a registered trademark of Abbott Laboratories.



# Improved impact on clinical outcomes and reduced cost of care associated with switching hypoallergenic amino acid-based formulas

Thakkar K., Cekola P., Boccella J., Desai A., Kumar P., Mondal S., Vijaykadam Y., Samal C., Klosterbuer A. *Sage Open Pediatrics* 2025;12: 1–11.

## Objectives


To evaluate the impact of switching amino acid-based formula (AAF) on clinical outcomes including GI intolerance, allergy symptoms, and health economic measures during the 2022 U.S. formula shortage.

## Study Design


402 Children, <18 years in post-acute care setting who switched from one AAF (EleCare®) to another one (Alfamino®) from June 2021- April 2022.

## Results


### Percent of GI Intolerance Symptoms




### Percent of Allergy Symptoms



### Mean Total Visits (Outpatient, Inpatient, Emergency Department, Urgent Care, Telemedicine, & Other)



### Total Associated Costs



## Discussion & Conclusion

Alfamino® had a greater % of medium chain triglycerides (MCTs) as total fat than the other AAF, and it is possible that this may have attributed to improved GI symptoms as MCTs help with fat absorption.

Children in post - acute care settings who transitioned to an alternate amino acid - based formula (Alfamino®) experienced significantly improved clinical outcomes, healthcare visits and associated costs.